Intravitreal Ziv-Aflibercept in Patients With Diabetic Macular Edema Refractory to Intravitreal Bevacizumab

Intravitreal Ziv-Aflibercept in Patients With Diabetic Macular Edema Refractory to Intravitreal Bevacizumab Publisher Pubmed

Ebrahimiadib N¹ ; Lashay A¹ ; Riaziesfahani H¹ ; Jamali S¹ ; Khodabandeh A¹ ; Zarei M¹ ; Roohipoor R¹ ; Khojasteh H¹ ; Bazvand F¹ ; Ojani M¹ ; Shahabinejad M¹ ; Modjtahedi BS^{2, 3} ; Davoudi S⁴ ; Riaziesfahani M⁵

Show Affiliations

1. Eye Research Center, Farabi Eye Hospital, Tehran University of Medical Sciences, Tehran, Iran
2. Department of Ophthalmology, Southern California Permanente Medical Group, Baldwin Park, CA, United States
3. Eye Monitoring Center, Kaiser Permanente Southern California, Baldwin Park, CA, United States
4. Department of Ophthalmology, University of Florida, Gainesville, FL, United States
5. Department of Ophthalmology, Gavin Herbert Eye Institute, University of California Irvine, Irvine, CA, United States

Source: Ophthalmic Surgery Lasers and Imaging Retina Published:2020

Abstract

BACKGROUND AND OBJECTIVE: To evaluate the efficacy of intravitreal ziv-aflibercept (IVZ) in patients with diabetic macular edema (DME) resistant to intravitreal bevacizumab (IVB). PATIENTS AND METHODS: This prospective study was conducted in patients with persistent DME. Patients were switched to IVZ no longer than 6 weeks after the last three consecutive monthly IVB treatments and monitored over a course of 12 weeks. Changes in best-corrected visual acuity (BCVA), central macular thickness (CMT), and macular volume on optical coherence tomography were compared. RESULTS: A total of 59 eyes (38 patients) were included. Mean BCVA improved from 0.84 to 0.71 logMAR (P = .001) after first IVZ treatment and remained significant. In a subgroup analysis, this significance was observed only in the group with baseline visual acuity of less than 20/50. Mean CMT decreased from 479 μm to 364 μm (P = .004) after the first IVZ injections and remained significant. CONCLUSION: IVZ may be best reserved for patients with persistent DME after initial failure with bevacizumab, with less likelihood for anatomic or functional improvement in those with mild persistent DME. Copyright © 2020 Slack Incorporated. All rights reserved.

Related Docs

1. Intravitreal Injection of Ziv-Aflibercept in the Treatment of Choroidal and Retinal Vascular Diseases, Journal of Current Ophthalmology (2017)

2. Evaluation of the Additive Effect of Interferon Α 2B With Monthly Intravitreal Injection of Bevacizumab in Refractory Diabetic Macular Edema, International Journal of Retina and Vitreous (2022)

3. The Short-Term Effects of Aflibercept on the Size of Choroidal Neovascularization Lesion in Treatment-Resistant Neovascular Age-Related Macular Degeneration As Determined by Spectral-Domain Optical Coherence Tomography, Lasers in Surgery and Medicine (2016)

4. Intravitreal Injection of Anti-Vascular Endothelial Growth Factor Agents for Ocular Vascular Diseases: Clinical Practice Guideline, Journal of Ophthalmic and Vision Research (2018)

5. Safety and Bioavailability of Complete and Half-Dose Intravitreal Ziv-Aflibercept in an Experimental Model: Contralateral Eye Study, Ophthalmic Surgery Lasers and Imaging Retina (2019)

Experts (# of related papers)

View all Related Experts

Hooshang Faghihi-Habibabad (2)

Elham Ashrafi (1)

Style	Citing Format
MLA	Ebrahimiadib N, et al.. "Intravitreal Ziv-Aflibercept in Patients With Diabetic Macular Edema Refractory to Intravitreal Bevacizumab." Ophthalmic Surgery Lasers and Imaging Retina, vol. 51, no. 3, 2020, pp. 145-151.
APA	Ebrahimiadib N, Lashay A, Riaziesfahani H, Jamali S, Khodabandeh A, Zarei M, Roohipoor R, Khojasteh H, Bazvand F, Ojani M, Shahabinejad M, Modjtahedi BS, Davoudi S, Riaziesfahani M (2020). Intravitreal Ziv-Aflibercept in Patients With Diabetic Macular Edema Refractory to Intravitreal Bevacizumab. Ophthalmic Surgery Lasers and Imaging Retina, 51(3), 145-151.
Chicago	Ebrahimiadib N, Lashay A, Riaziesfahani H, Jamali S, Khodabandeh A, Zarei M, Roohipoor R, et al.. "Intravitreal Ziv-Aflibercept in Patients With Diabetic Macular Edema Refractory to Intravitreal Bevacizumab." Ophthalmic Surgery Lasers and Imaging Retina 51, no. 3 (2020): 145-151.
Harvard	Ebrahimiadib N et al. (2020) 'Intravitreal Ziv-Aflibercept in Patients With Diabetic Macular Edema Refractory to Intravitreal Bevacizumab', Ophthalmic Surgery Lasers and Imaging Retina, 51(3), pp. 145-151.
Vancouver	Ebrahimiadib N, Lashay A, Riaziesfahani H, Jamali S, Khodabandeh A, Zarei M, et al.. Intravitreal Ziv-Aflibercept in Patients With Diabetic Macular Edema Refractory to Intravitreal Bevacizumab. Ophthalmic Surgery Lasers and Imaging Retina. 2020;51(3):145-151.
BibTex	@article{ author = {Ebrahimiadib N and Lashay A and Riaziesfahani H and Jamali S and Khodabandeh A and Zarei M and Roohipoor R and Khojasteh H and Bazvand F and Ojani M and Shahabinejad M and Modjtahedi BS and Davoudi S and Riaziesfahani M}, title = {Intravitreal Ziv-Aflibercept in Patients With Diabetic Macular Edema Refractory to Intravitreal Bevacizumab}, journal = {Ophthalmic Surgery Lasers and Imaging Retina}, volume = {51}, number = {3}, pages = {145-151}, year = {2020} }
RIS	TY - JOUR AU - Ebrahimiadib N AU - Lashay A AU - Riaziesfahani H AU - Jamali S AU - Khodabandeh A AU - Zarei M AU - Roohipoor R AU - Khojasteh H AU - Bazvand F AU - Ojani M AU - Shahabinejad M AU - Modjtahedi BS AU - Davoudi S AU - Riaziesfahani M TI - Intravitreal Ziv-Aflibercept in Patients With Diabetic Macular Edema Refractory to Intravitreal Bevacizumab JO - Ophthalmic Surgery Lasers and Imaging Retina VL - 51 IS - 3 SP - 145 EP - 151 PY - 2020 ER -

Science Communicator Platform

Authors

Authors Affiliations

Abstract